PR90814

Texas Cardiac Arrhythmia Institute leader participates in clinical trial for world's first artificial intelligence technology for complex cardiac arrhythmia procedures

AUSTIN, Texas, July 23, 2021 /PRNewswire=KYODO JBN/ --

The leader of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's

Medical Center (

https://c212.net/c/link/?t=0&l=en&o=3236884-1&h=4075004528&u=https%3A%2F%2Ftcainstitute.com%2F&a=Texas+Cardiac+Arrhythmia+Institute+(TCAI)+at+St.+David%27s+Medical+Center

) recently led a clinical study to evaluate the world's first data-driven

artificial intelligence (AI) platform for cardiac electrophysiology (EP)

procedures. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac

electrophysiologist and executive medical director of TCAI, conducted the

first-in-human trial in Europe.

The NeuTrace EP Platform technology is designed to better guide

electrophysiologists during complex cardiac EP procedures to help improve

safety and reduce procedure times.

"This first-of-its-kind innovative AI-driven EP platform allows us to enhance

ablation by providing advanced metrics and comprehensive patient data in real

time for a more precise delivery during complex ablation procedures," Dr.

Natale said. "The AI-guided cardiac mapping technology is designed to provide a

much safer option for patients and ensure the best possible outcomes."

The EP platform is built on the foundation of an underlying "Data Biome" and

leverages AI to provide the most high-fidelity signal quality, advanced

metrics, improved visualizations and comprehensive patient data—including real

time, electrical signals and 3-D navigation—for a more accurate view of the

underlying characteristics of the heart during all EP procedures. The mapping

application is one of several "apps" on the EP platform and is designed to

provide a more tailored and accurate approach to mapping and ablation, with the

goal of increasing accuracy and improving patient outcomes—from diagnosis

through ablation and beyond.

The EP platform aims to assist in the treatment of more than 2.7 million

patients in the U.S. with atrial fibrillation, in addition to those who require

ablation procedures. The technology is currently being readied for submission

to the FDA for marketing authorization.

Media Contact:

Tina Shively

Elizabeth Christian Public Relations

TShively@EChristianPR.com

+1.845.216.1850 cell

SOURCE: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center